Composition for promoting ketone body production

Patent metadata

Field	Value
Publication number	US-11224581-B2
Application number	US-201716326260-A
Country	US
Kind code	B2
Filing date	Aug 18, 2017
Priority date	Aug 19, 2016
Publication date	Jan 18, 2022
Grant date	Jan 18, 2022

Abstract

An object of the present invention is to provide a novel composition for promoting ketone body production. The present invention provides a composition for use in promoting ketone body production, comprising one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition according to the present invention may further comprise either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

First claim

The invention claimed is:

1. A method for promoting ketone body production to treat, prevent, or improve a disease or symptom that can be treated, prevented or improved by promoting ketone body production in a subject in need thereof, comprising feeding or administering to the subject one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid in an amount effective to treat, prevent, or improve the disease or symptom.

2. The method of claim 1 , further comprising feeding or administering to the subject either or both of a medium-chain fatty acid and a medium-chain fatty acid ester in an amount effective to treat, prevent, or improve the disease or symptom.

3. The method of claim 1 , wherein the amino acid is provided in a food product.

4. The method of claim 2 , wherein the amino acid and either or both of the medium-chain fatty acid and medium-chain fatty acid ester are provided in a food product.

5. The method of claim 2 , wherein the amino acid and the a medium-chain fatty acid and/or a medium-chain fatty acid ester are administered in a molar ratio [(A)/(B)] of the amino acid(s) (A) to the medium-chain fatty acid and/or medium-chain fatty acid ester (B) ranges from 0.1 to 0.5.

6. The method of claim 5 , wherein the amino acid and either or both of the a medium-chain fatty acid and a medium-chain fatty acid ester are provided in a food product.

7. The method of claim 1 , wherein the disease and symptom are one or more selected from the group consisting of childhood epilepsy, intractable epilepsy, glucose transporter 1 (GLUT1) deficiency, pyruvate dehydrogenase complex disorder, Alzheimer's disease, neurodegenerative disease, mild cognitive impairment, Parkinson's disease, traumatic brain injury, cancer, depression, autism, migraine, amyotrophic lateral sclerosis, narcolepsy, diabetes, heart failure, myocardial infarction, angina pectoris, and obesity.

Assignees

• Meiji Co Ltd

Inventors

• Nakamura Kentaro
• Ashida Kinya
• SASAYAMA Akina
• Saito Yuri

Classifications

• A61P25/24

  Antidepressants · CPC title

• A61K31/20

  having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P25/06

  Antimigraine agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title